IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Invivyd, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.61−0.01 (-1.39%)
Close on Oct 19, 2026
- Market cap
- $195.47M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
79.0%
233M of 295M shares
Institutional holders
125
34 new, 45 sold out
Net institutional buying
38M
In Q2 2026
Insider trades, 12 months
1 buys · 20 sales
Net sold $406.07K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| David Kroin | 9,722,254 | 8.10% | 13G (passive) amendment | Mar 31, 2025 |
| Lampert Mark N | 29,571,826 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| RA Capital Management, L.P. | 28,857,208 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Bvf Inc/Il | 25,525,000 | 9.00% | 13G (passive) amendment | Dec 31, 2025 |
| Janus Henderson Group PLC | 25,383,077 | 12.10% | 13G (passive) amendment | Sep 30, 2025 |
| Perceptive Life Sciences Master Fund, Ltd. | 21,785,166 | 7.90% | 13G (passive) | Nov 18, 2025 |
| Peter Kolchinsky | 21,342,442 | 7.00% | 13G (passive) amendment | Mar 31, 2026 |
| RA Capital Healthcare Fund, L.P. | 21,338,288 | 9.90% | 13G (passive) | Aug 22, 2025 |
| Adimab, LLC | 20,262,170 | 7.30% | 13D (active) amendment | Dec 23, 2025 |
| Maverick Capital Management, LLC | 18,970,913 | 6.70% | 13G (passive) amendment | Dec 31, 2025 |
| Joseph Edelman | 18,490,636 | 6.30% | 13G (passive) amendment | Jun 30, 2026 |
| Steven A. Cohen | 16,653,036 | 6.00% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 16,124,696 | 5.50% | 13G (passive) | Jun 30, 2026 |
| Soleus GP, LLC | 10,850,000 | 5.10% | 13G (passive) | Oct 10, 2025 |
| Lee S. Ainslie III | 10,229,118 | 8.50% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IVVD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 34,173,104 | 11.59% | $30.05M | New | 0.01% |
| Bvf Inc/Il | 28,165,000 | 9.56% | $24.57M | +8,640,000 | 0.63% |
| Maverick Capital Ltd | 18,970,913 | 6.44% | $16.55M | – | 0.15% |
| Perceptive Advisors LLC | 18,490,636 | 6.27% | $16.13M | −2,368,667 | 0.24% |
| BlackRock, Inc. | 16,134,885 | 5.47% | $14.08M | +11,853,095 | 0.00% |
| Vanguard Capital Management LLC | 10,496,507 | 3.56% | $9.15M | +422,181 | 0.00% |
| M28 Capital Management LP | 9,248,250 | 3.14% | $8.07M | – | 17.11% |
| Saturn V Capital Management LP | 8,392,288 | 2.85% | $7.32M | −2,556,796 | 1.05% |
| Soleus Capital Management, L.P. | 7,708,727 | 2.62% | $6.73M | – | 0.23% |
| Point72 Asset Management, L.P. | 7,542,061 | 2.56% | $6.58M | +7,498,130 | 0.01% |
| Morgan Stanley | 5,730,948 | 1.94% | $5.00M | +2,342,766 | 0.00% |
| Geode Capital Management, LLC | 5,418,774 | 1.84% | $4.73M | +2,949,847 | 0.00% |
| Siren, L.L.C. | 5,000,000 | 1.70% | $4.36M | +1,000,000 | 0.09% |
| Driehaus Capital Management LLC | 4,806,543 | 1.63% | $4.19M | −3,630,351 | 0.02% |
| ADAR1 Capital Management, LLC | 3,807,427 | 1.29% | $3.32M | −15,000 | 0.15% |
| Adage Capital Partners Gp, L.L.C. | 3,661,480 | 1.24% | $3.19M | – | 0.00% |
| Citadel Advisors LLC | 3,580,941 | 1.21% | $3.12M | +1,991,366 | 0.00% |
| State Street Corp | 3,457,428 | 1.17% | $3.02M | −3,478,220 | 0.00% |
| Qube Research & Technologies Ltd | 3,320,238 | 1.13% | $2.90M | +633,043 | 0.00% |
| Ikarian Capital, LLC | 2,656,570 | 0.90% | $2.32M | – | 0.25% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 125 | 233M | 79.0% | 34 / 38 | 26 / 45 | 80M | 42M |
| Q1 2026 | 140 | 228M | 77.5% | 42 / 40 | 25 / 16 | 42M | 43M |
| Q4 2025 | 116 | 240M | 81.5% | 49 / 27 | 18 / 8 | 115M | 12M |
| Q3 2025 | 78 | 149M | 50.5% | 26 / 21 | 17 / 16 | 102M | 14M |
| Q2 2025 | 68 | 60M | 20.5% | 17 / 13 | 26 / 28 | 4M | 13M |
| Q1 2025 | 79 | 70M | 23.9% | 17 / 21 | 26 / 14 | 3M | 9M |
| Q4 2024 | 77 | 77M | 26.1% | 13 / 23 | 20 / 12 | 14M | 8M |
| Q3 2024 | 76 | 72M | 24.3% | 15 / 18 | 23 / 17 | 6M | 6M |
| Q2 2024 | 80 | 76M | 25.8% | 23 / 28 | 18 / 29 | 13M | 10M |
| Q1 2024 | 86 | 73M | 24.6% | 32 / 25 | 18 / 5 | 20M | 3M |
| Q4 2023 | 59 | 56M | 18.9% | 11 / 18 | 16 / 10 | 6M | 4M |
| Q3 2023 | 58 | 53M | 18.1% | 9 / 12 | 20 / 8 | 4M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IVVD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 7,785,522 | 2.64% | $6.79M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 5,373,005 | 1.82% | $4.69M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,383,653 | 0.81% | $2.08M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,288,478 | 0.78% | $1.22M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 2,025,862 | 0.69% | $1.77M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,103,785 | 0.37% | $1.26M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 706,398 | 0.24% | $616.26K | 0.04% | Jun 30, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 585,533 | 0.20% | $510.82K | 0.00% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 538,493 | 0.18% | $288.09K | 0.00% | Jul 31, 2026 |
| Emerald Growth Fund | 428,847 | 0.15% | $600.39K | 0.04% | Apr 30, 2026 |
| Emerald Growth Fund | 428,847 | 0.15% | $229.43K | 0.02% | Jul 31, 2026 |
| Virtus Biotech Clinical Trials Etf | 403,655 | 0.14% | $215.96K | 0.47% | Jul 31, 2026 |
| Master Small Cap Index Series | 393,460 | 0.13% | $343.25K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 390,357 | 0.13% | $445.01K | 0.00% | May 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 353,119 | 0.12% | $188.92K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marc Elia | Chief Executive Officer, Director | 9,248,250 | 3.14% | Sep 1, 2026 |
| William E. Duke | Chief Financial Officer | 168,937 | 0.06% | Aug 18, 2026 |
| Robert D. Allen III | Chief Scientific Officer | 178,765 | 0.06% | Aug 18, 2026 |
| Jill Andersen | Chief Legal Officer, Secretary | 284,274 | 0.10% | Aug 18, 2026 |
| Timothy Edward Lee | Chief Commercial Officer | 178,937 | 0.06% | Aug 18, 2026 |
| Julie Green | Chief Human Resources Officer | 168,937 | 0.06% | Aug 18, 2026 |
| Michael Mina | CMO and Chief Epidemiologist | – | – | Aug 4, 2026 |
| Ian Sheffield | Director | – | – | Sep 2, 2026 |
| Terrance McGuire | Director | 3,066,757 | 1.04% | May 21, 2026 |
| Kevin F. McLaughlin | Director | 50,000 | 0.02% | May 21, 2026 |
| Paul Bolno | Director | – | – | May 21, 2026 |
| Ajay Royan | Director | 11,241,580 | 3.81% | May 21, 2026 |
| Tamsin Berry | Director | – | – | May 21, 2026 |
| Christine Lindenboom | Director | – | – | May 22, 2025 |
| Capital Management LP M28 | – | 6,398,250 | 2.17% | May 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Julie Green Chief Human Resources Officer | Aug 18, 2026 | Sale(10b5-1 plan) | −18,425 | $0.84 | $15.48K | 168,937 |
| Timothy Edward Lee Chief Commercial Officer | Aug 18, 2026 | Sale(10b5-1 plan) | −18,425 | $0.84 | $15.48K | 178,937 |
| Jill Andersen Chief Legal Officer, Secretary | Aug 18, 2026 | Sale(10b5-1 plan) | −30,706 | $0.84 | $25.79K | 283,774 |
| Robert D. Allen III Chief Scientific Officer | Aug 18, 2026 | Sale(10b5-1 plan) | −17,043 | $0.84 | $14.32K | 178,765 |
| William E. Duke Chief Financial Officer | Aug 18, 2026 | Sale(10b5-1 plan) | −18,425 | $0.84 | $15.48K | 168,937 |
| Julie Green Chief Human Resources Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −22,355 | $0.72 | $16.10K | 187,362 |
| Timothy Edward Lee Chief Commercial Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −22,355 | $0.72 | $16.10K | 197,362 |
| Jill Andersen Chief Legal Officer, Secretary | Aug 17, 2026 | Sale(10b5-1 plan) | −37,256 | $0.72 | $26.82K | 314,480 |
| Robert D. Allen III Chief Scientific Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −20,679 | $0.72 | $14.89K | 195,808 |
| William E. Duke Chief Financial Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −22,355 | $0.72 | $16.10K | 187,362 |
| Julie Green Chief Human Resources Officer | Aug 15, 2026 | Option exercise | +102,000 | – | – | 209,717 |
| Timothy Edward Lee Chief Commercial Officer | Aug 15, 2026 | Option exercise | +102,000 | – | – | 219,717 |
| Jill Andersen Chief Legal Officer, Secretary | Aug 15, 2026 | Option exercise | +170,000 | – | – | 351,736 |
| Robert D. Allen III Chief Scientific Officer | Aug 15, 2026 | Option exercise | +102,000 | – | – | 216,487 |
| William E. Duke Chief Financial Officer | Aug 15, 2026 | Option exercise | +102,000 | – | – | 209,717 |
| Robert D. Allen III Chief Scientific Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −19,392 | $1.58 | $30.64K | 114,487 |
| William E. Duke Chief Financial Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −20,964 | $1.58 | $33.12K | 107,717 |
| Julie Green Chief Human Resources Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −20,964 | $1.58 | $33.12K | 107,717 |
| Jill Andersen Chief Legal Officer, Secretary | Feb 18, 2026 | Sale(10b5-1 plan) | −34,939 | $1.58 | $55.20K | 181,736 |
| Timothy Edward Lee Chief Commercial Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −20,964 | $1.58 | $33.12K | 117,717 |
| Robert D. Allen III Chief Scientific Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −18,189 | $1.54 | $28.01K | 133,879 |
| William E. Duke Chief Financial Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −19,663 | $1.54 | $30.28K | 128,681 |
| Julie Green Chief Human Resources Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −19,663 | $1.54 | $30.28K | 128,681 |
| Jill Andersen Chief Legal Officer, Secretary | Feb 17, 2026 | Sale(10b5-1 plan) | −32,771 | $1.54 | $50.47K | 216,675 |
| Timothy Edward Lee Chief Commercial Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −19,663 | $1.54 | $30.28K | 138,681 |
| Robert D. Allen III Chief Scientific Officer | Feb 15, 2026 | Option exercise | +99,000 | – | – | 152,068 |
| William E. Duke Chief Financial Officer | Feb 15, 2026 | Option exercise | +99,000 | – | – | 148,344 |
| Julie Green Chief Human Resources Officer | Feb 15, 2026 | Option exercise | +99,000 | – | – | 148,344 |
| Jill Andersen Chief Legal Officer, Secretary | Feb 15, 2026 | Option exercise | +165,000 | – | – | 249,446 |
| Timothy Edward Lee Chief Commercial Officer | Feb 15, 2026 | Option exercise | +99,000 | – | – | 158,344 |
| Kevin F. McLaughlin Director | Nov 19, 2025 | Buy | +50,000 | $2.50 | $125.00K | 50,000 |
| Timothy Edward Lee Chief Commercial Officer | Aug 19, 2025 | Sale(10b5-1 plan) | −29,643 | $0.57 | $16.90K | 59,344 |
| Julie Green Chief Human Resources Officer | Aug 19, 2025 | Sale(10b5-1 plan) | −29,643 | $0.57 | $16.90K | 49,344 |
| Robert D. Allen III Chief Scientific Officer | Aug 19, 2025 | Sale(10b5-1 plan) | −27,420 | $0.57 | $15.63K | 53,068 |
| Jill Andersen Chief Legal Officer, Secretary | Aug 19, 2025 | Sale(10b5-1 plan) | −49,402 | $0.57 | $28.16K | 84,446 |
| William E. Duke Chief Financial Officer | Aug 19, 2025 | Sale(10b5-1 plan) | −29,643 | $0.57 | $16.90K | 49,344 |
| Timothy Edward Lee Chief Commercial Officer | Aug 18, 2025 | Sale(10b5-1 plan) | −20,013 | $0.65 | $13.01K | 88,987 |
| Julie Green Chief Human Resources Officer | Aug 18, 2025 | Sale(10b5-1 plan) | −20,013 | $0.65 | $13.01K | 78,987 |
| Robert D. Allen III Chief Scientific Officer | Aug 18, 2025 | Sale(10b5-1 plan) | −18,512 | $0.65 | $12.03K | 80,488 |
| Jill Andersen Chief Legal Officer, Secretary | Aug 18, 2025 | Sale(10b5-1 plan) | −33,352 | $0.65 | $21.68K | 133,848 |
| William E. Duke Chief Financial Officer | Aug 18, 2025 | Sale(10b5-1 plan) | −20,013 | $0.65 | $13.01K | 78,987 |
| Timothy Edward Lee Chief Commercial Officer | Aug 15, 2025 | Option exercise | +99,000 | – | – | 109,000 |
| Julie Green Chief Human Resources Officer | Aug 15, 2025 | Option exercise | +99,000 | – | – | 99,000 |
| Robert D. Allen III Chief Scientific Officer | Aug 15, 2025 | Option exercise | +99,000 | – | – | 99,000 |
| Jill Andersen Chief Legal Officer, Secretary | Aug 15, 2025 | Option exercise | +165,000 | – | – | 167,200 |
| William E. Duke Chief Financial Officer | Aug 15, 2025 | Option exercise | +99,000 | – | – | 99,000 |
| Terrance McGuire Director | Dec 31, 2024 | Sale | −103,474 | $0.45 | $46.56K | 3,066,757 |
| Terrance McGuire Director | Dec 30, 2024 | Sale | −86,545 | $0.48 | $41.54K | 3,170,231 |
| Terrance McGuire Director | Dec 27, 2024 | Sale | −83,744 | $0.52 | $43.55K | 3,256,776 |
| Terrance McGuire Director | Dec 26, 2024 | Sale | −83,817 | $0.54 | $45.26K | 3,340,520 |
| Terrance McGuire Director | Dec 24, 2024 | Sale | −68,161 | $0.51 | $34.76K | 3,424,337 |
| Terrance McGuire Director | Dec 23, 2024 | Sale | −75,776 | $0.45 | $34.10K | 3,492,498 |
| Terrance McGuire Director | Dec 20, 2024 | Sale | −119,805 | $0.42 | $50.32K | 3,568,274 |
| Terrance McGuire Director | Dec 19, 2024 | Sale | −152,067 | $0.43 | $65.39K | 3,688,079 |
| Terrance McGuire Director | Dec 18, 2024 | Sale | −74,764 | $0.47 | $35.14K | 3,840,146 |
| Terrance McGuire Director | Dec 17, 2024 | Sale | −97,410 | $0.48 | $46.76K | 3,914,910 |
| Terrance McGuire Director | Dec 16, 2024 | Sale | −65,359 | $0.47 | $30.72K | 4,012,320 |
| Terrance McGuire Director | Dec 12, 2024 | Sale | −125,000 | $0.58 | $72.50K | 4,077,679 |
| Terrance McGuire Director | Dec 11, 2024 | Sale | −160,400 | $0.59 | $94.64K | 4,202,679 |
| Terrance McGuire Director | Dec 10, 2024 | Sale | −175,000 | $0.59 | $103.25K | 4,363,079 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Timothy Edward Lee Officer | Aug 17, 2026 | 40,800 | $29.41K | Aug 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Julie Green Officer | Aug 17, 2026 | 40,800 | $29.41K | Aug 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| William E. Duke Officer | Aug 17, 2026 | 40,800 | $29.41K | Aug 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Jill Andersen Officer | Aug 17, 2026 | 68,001 | $49.02K | Aug 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Robert D. Allen III Officer | Aug 17, 2026 | 37,741 | $27.21K | Aug 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Julie Green Officer | Feb 17, 2026 | 39,600 | $61.78K | Feb 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Robert D. Allen III Officer | Feb 17, 2026 | 36,630 | $57.14K | Feb 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Timothy Edward Lee Officer | Feb 17, 2026 | 39,600 | $61.78K | Feb 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| William E. Duke Officer | Feb 17, 2026 | 39,600 | $61.78K | Feb 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Jill Andersen Officer | Feb 17, 2026 | 66,000 | $102.96K | Feb 17, 2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Adimab, Llc 10% Stockholder | Dec 23, 2025 | 192,320 | $577.50K | Dec 23, 2025 | Private Acquisition from Issuer/Affiliate |
| Adimab, Llc 10% Stockholder | Nov 17, 2025 | 1,233,416 | $3.70M | Nov 17, 2025 | Private Acquisition from Issuer/Affiliate |
| Julie Green Officer | Aug 18, 2025 | 39,600 | $28.00K | Aug 18, 2025 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Robert D. Allen III Officer | Aug 18, 2025 | 36,631 | $25.90K | Aug 18, 2025 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |
| Timothy Edward Lee Officer | Aug 18, 2025 | 39,600 | $28.00K | Aug 18, 2025 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan |